Login to Your Account



Clinic Roundup


Tuesday, September 27, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., completed patient enrollment in its second randomized Phase II trial for bavituximab. The company said 66 patients with previously untreated genotype-1 hepatitis C virus infection were treated with 12 weeks of ribavirin in combination with bavituximab or pegylated interferon alpha-2a.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription